DOCSLIB.ORG

Final Program and Book of Abstracts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Final Program and Book of Abstracts JOINT MEETING OF THE AUSTRIAN AND GERMAN PHARMACEUTICAL SOCIETIES September 20 – 23, 2011 University of Innsbruck, Austria "Shaping the future – Trends and perspectives in pharmaceutical sciences" FINAL PROGRAM AND BOOK OF ABSTRACTS ORGANIZATION Presidents Prof. H. Stuppner, Innsbruck (ÖPhG) Prof. M. Schubert-Zsilavecz (DPhG) Organizing Committee Prof. G. Ecker (Austria) Prof. S. Glasl-Tazreiter (Austria) Prof. U. Griesser (Austria) Ing. E. Gstrein (Austria) S. Handke (Germany) Dr. T. Maschke (Germany) Dr. S. Schwaiger (Austria) Dr. M. Stein (Germany) Scientific Committee Prof. S. Alban (Vice President, DPhG) Prof. R. Bauer (Graz, Austria) Prof. A. Bernkop-Schnürch (Innsbruck, Austria) Prof. T. Dingermann (Frankfurt, Germany) Prof. Dr. V. Dirsch (Vienna, Austria) Prof. G. Ecker (Vice President,ÖPhG) Prof. S. Glasl-Tazreiter (General Secretary, ÖPhG) Prof. R. Gust (Innsbruck, Austria) Prof. U. Holzgrabe (Würzburg, Germany) Prof. A. Kungl (Graz, Austria) Prof. R. Lemmens-Gruber (Vienna, Austria) Prof. A. Link (General Secretary, DPhG) Prof. C. Noe (Vienna, Austria) Prof. M. Schubert-Zsilavecz (President, DPhG) Prof. N. Singewald (Innsbruck, Austria) Prof. D. Steinhilber (Frankfurt, Germany) Prof. H. Stuppner (President, ÖPhG) Prof. H. Viernstein (Vienna, Austria) Prof. O. Werz (Jena, Germany) Prof. A. Zimmer (Graz, Austria) Organizing Secretariat University of Innsbruck Institute of Pharmacy/Pharmacognosy Innrain 52c A-6020 Innsbruck Email: [email protected] Homepage: www.uibk.ac.at/news/oephg-dphg2011 CONFERENCE VENUES University of Innsbruck Campus Universitätsstrasse 15 and Karl-Rahner-Platz 3 6020 Innsbruck, Austria Campus Universitätsstrasse 15 Karl- Rahner- Platz 3 Campus map of conference venues REGISTRATION AND OFFICE HOURS University of Innsbruck Campus Universitätsstrasse 15 Room O.E-18 (Studierzone) 6020 Innsbruck, Austria Tuesday, September 20 2011 11:00 – 18:00 Wednesday, September 21 2011 08:00 – 18:00 Thursday, September 22 2011 08:00 – 18:00 Friday, September 23 2011 08:00 – 12:00 WELCOME Dear Colleagues, In spite of the increasing expenses for research and development and the growing scientific knowledge, the number of approvals of new drugs has been steadily declining in the last 10 years. The increasing regulatory requirements and ascending expenses for clinical trials are counted among the main reasons for the rising costs. The pharmaceutical industry tried at first to counterbalance this innovation gap with higher research budgets, then with merging and acquisition of smaller firms and innovative biotechnological companies and finally with reorganization of the R&D processes. For some time now the pharmaceutical industry focuses more and more on strategic co-operations with universities and their pharmaceutical institutes in order to meet its demand for innovation. Future progress in drug research will depend more and more on the extensive comprehension of the complex causes for diseases and the translation of these insights in clinical trials. New co-operation models are needed in order to incorporate the findings of excellent fundamental research into the development of innovative drugs in Europe. It is the superior goal of the Joint Meeting of the Austrian and German Pharmaceutical Societies to present outstanding pharmaceutical research key aspects of Austrian and German universities with the aid of thematically focused short presentations and to provide by this way a basis for co-operation. In addition – according to the motto of our meeting – international outstanding scientists will give plenary speeches on trends and perspectives in pharmaceutical sciences. We thank our co-operation partners, last but not least the Pharmaceutical Society of Japan, for supporting the preparation and conduction of our meeting. We wish all participants of the meeting fruitful scientific discussions that may serve to tighten and expand pharmaceutical networks. Furthermore we wish all participants a pleasant stay in one of the most beautiful cities of the Alps area, may be even the most beautiful! Prof. Hermann Stuppner Prof. Manfred Schubert-Zsilavecz President of the ÖPhG President of the DPhG I INDEX GENERAL INFORMATIONS, ACKNOWLEDGEMENTS, PRESYMPOSIA............ II - XIV SCIENTIFIC PROGRAM ................................................................................................... 1 LIST OF SCIENTIFIC CONTRIBUTIONS ....................................................................... 17 PLENARY LECTURES .................................................................................................... 37 KEY LECTURES ............................................................................................................. 47 ABSTRACTS OF SHORT LECTURES ........................................................................... 51 Inflammation ............................................................................................................ 52 G-Proteins ............................................................................................................... 57 Natural Products ..................................................................................................... 62 Transporter .............................................................................................................. 67 Nanomedicine ......................................................................................................... 70 OMICs and Biopharmaceutics ................................................................................. 74 Computer Aided Drug Design ................................................................................. 77 Miscellaneous Topics .............................................................................................. 79 ABSTRACTS OF PRE-SYMPOSIA ................................................................................ 85 WORKSHOPS ............................................................................................................... 101 ABSTRACTS OF POSTERS ......................................................................................... 105 Inflammation .......................................................................................................... 106 G-Proteins ............................................................................................................. 118 Natural Products ................................................................................................... 136 Transporter ............................................................................................................ 169 Nanomedicine ....................................................................................................... 176 OMICs and Biopharmaceutics ............................................................................... 197 Computer Aided Drug Design ............................................................................... 209 Counterfeit Drugs .................................................................................................. 231 Miscellaneous - Analytics ...................................................................................... 232 Miscellaneous - Clinical Pharmacy ........................................................................ 236 Miscellaneous – Pharm./ Med. Chemistry ............................................................. 246 Miscellaneous - Pharmaceutical Technology ........................................................ 262 Miscellaneous - Pharmacology ............................................................................. 282 INDEX OF AUTHORS ................................................................................................... 287 II GENERAL INFORMATIONS Exhibitions University of Innsbruck Campus Universitätsstrasse 15, Foyer 6020 Innsbruck Oral presentations PC, beamer and overhead projector are available. Please contact the information desk to deliver your presentations (MS PowerPoint only) at latest in the morning the day your presentation is scheduled. Plenary Lectures: 45 min (40 + 5 min discussion) Key Lectures: 25 min (20 + 5 min discussion) Short lectures 15 min (12 + 3 min discussion) Posters Two poster sessions are going to be held: • Wednesday, September 21 2011, 15.00 – 16.45 • Thursday, September 22 2011, 14.45 – 16.30 Posters will be on display in the Foyer, on the first and on the second floor of the Campus Universitätsstrasse 15. Please mount the posters for the first session until Wednesday, September 21 2011, 12:00 and for the second session on Thursday, September 22 2011, until 12:00. The necessary material to fix the posters will be provided by the organizers. The poster numbers are indicated in the list of poster presentations in the final program. Presenting authors are asked to be present at their posters during the poster sessions. Conference dinner The conference dinner will take place on Thursday evening, September 22 2011 at 19.30 in the restaurant “Stiftskeller”, Stiftgasse 1, 6020 Innsbruck, Austria. Language The congress language is English, no simultaneous translation will be provided. Badges Badges will be issued to all registered participants and enable access to all scientific sessions. Members of the Organizing Committee wear T-Shirts with the Logo from the University of Innsbruck. Liability The Organizers of the Symposium cannot be held responsible for any loss, theft, damage or injury to any person or property during the conference, whatever the cause may be. The liability
Load more

Recommended publications
  • SFB 1074 Renewal Application PI Profiles 2016-2020
    General Information Name: Prof. Dr. med. Klaus-Michael Debatin Date of Birth: 06.12.1952 Gender: Male Address: Department of Pediatrics and Adolescent Medicine, Ulm University, Eythstrasse 24, 89075 Ulm/Germany Phone: +49 731 500 57001 E-Mail: [email protected] Current Positions: Chairman, Department of Pediatrics, Ulm University Medical Director, University Children’s Hospital Ulm Deputy Coordinating Investigator, Collaborative Research Center (SFB) 1074 “Experimental models and clinical translation in leukemia” Academic Education 1971 - 1978 Medical School, Universities of Ulm, Freiburg and Heidelberg Academic Degrees 1997 Professor of Pediatrics, Ulm University 1990 Habilitation in Pediatrics, University of Heidelberg 1979 Doctorate degree (Dr. med.), University of Heidelberg Professional Experience 2013-2015 CEO and Medical Director, University Medical Center Ulm 2010-2013 Deputy Medical Director, University Medical Center Ulm 2010-2014 Vice President Medicine, Ulm University 2004-2010 Dean, Medical Faculty, Ulm University 2003-2005 Chairman, Science Committee of the Medical Faculty, Ulm University 2002-2004 Vice Dean, Medical Faculty, Ulm University 1995-2002 Head, Division of Molecular Oncology, German Cancer Research Center 1997 Visiting Professor, St. Jude Children’s Research Hospital, Memphis Since 1997 Chairman, Department of Pediatrics, Ulm University Physician-in-chief of the University Children’s Hospital Ulm 1994-1997 Head, Hematology/Oncology Section, University Children's Hospital, Heidelberg 1990-1994
    [Show full text]
  • Chemotherapy for Breast Cancer
    INFORMATION AND ADVICE Austria CHEMOTHERAPY Brustkrebs Deutschland e. V. Österreichische Krebshilfe-Gesellschaft [Breast Cancer Germany, registered association] [Austrian Cancer Aid Association] FOR BREAST CANCER – Lise-Meitner-Str. 7 Tuchlauben 19 HOW DO I DEAL 85662 Hohenbrunn (district of Munich) AT-1010 Vienna Tel.: +49 (0) 89 / 41 61 98 00 Tel.: +43 (0) 1 / 796 64 50 WITH SIDE EFFECTS? Fax: +49 (0) 89 / 41 61 98 01 Fax: +43 (0) 1 / 796 64 50-9 Free hotline: 0800 0 117 112 www.krebshilfe.net E-Mail: [email protected] DE-HAL-18-00041 (V2.0): 12/2020; HAL0129B www.brustkrebsdeutschland.de Switzerland Deutsche Krebsgesellschaft e. V. [German Cancer Association, registered association] Krebsliga Schweiz Kuno-Fischer-Str. 8 [Cancer League Switzerland] 14057 Berlin Effingerstrasse 40 Tel: + 49 (0) 30 322932-90 CH-3001 Bern Fax: + 49 (0) 30 3229329-22 Tel.: +41 (0) 31 389 91 00 www.krebsgesellschaft.de Fax: +41 (0) 31 389 91 60 [email protected] Krebsinformationsdienst Deutsches Krebsforschungszentrum Cancer telephone and helpline [Cancer Information Service Free hotline: +41 (0) 800 11 88 11 German Cancer Research Centre] E-mail: [email protected] Im Neuenheimer Feld 280 Forum: www.krebsforum.ch 69120 Heidelberg Free hotline: +49 (0) 800 / 420 30 40 www.krebsinformationsdienst.de Stiftung Deutsche Krebshilfe-Infonetz Krebs [German Cancer Aid Foundation-Cancer Information Network] Buschstr. 32 53113 Bonn Tel.: +49 (0) 800 / 80 70 88 77 (free of charge) Mon. to Fri. 8.00 – 17.00 www.infonetz-krebs.de Distribution in Germany: Distribution in Austria: Distribution in Switzerland: Englisch Eisai GmbH Eisai GesmbH, Saturn Tower Eisai Pharma AG Edmund-Rumpler-Straße 3 Leonard-Bernstein-Straße 10 Leutschenbachstrasse 95 60549 Frankfurt am Main A-1220 Vienna CH-8050 Zurich [email protected] [email protected] Tel.: +41 (0) 44 / 306 12 12 INTRODUCTION HELP WITH SELF-HELP Palliative chemotherapy: Therapy with cytostatics aimed at prolonging survival time and improving quality of life.
    [Show full text]
  • Covalent Agonists for Studying G Protein-Coupled Receptor Activation
    Covalent agonists for studying G protein-coupled receptor activation Dietmar Weicherta, Andrew C. Kruseb, Aashish Manglikb, Christine Hillera, Cheng Zhangb, Harald Hübnera, Brian K. Kobilkab,1, and Peter Gmeinera,1 aDepartment of Chemistry and Pharmacy, Friedrich Alexander University, 91052 Erlangen, Germany; and bDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305 Contributed by Brian K. Kobilka, June 6, 2014 (sent for review April 21, 2014) Structural studies on G protein-coupled receptors (GPCRs) provide Disulfide-based cross-linking approaches (17, 18) offer important insights into the architecture and function of these the advantage that the covalent binding of disulfide-containing important drug targets. However, the crystallization of GPCRs in compounds is chemoselective for cysteine and enforced by the active states is particularly challenging, requiring the formation of affinity of the ligand-pharmacophore rather than by the elec- stable and conformationally homogeneous ligand-receptor com- trophilicity of the cross-linking function (19). We refer to the plexes. Native hormones, neurotransmitters, and synthetic ago- described ligands as covalent rather than irreversible agonists nists that bind with low affinity are ineffective at stabilizing an because cleavage may be promoted by reducing agents and the active state for crystallogenesis. To promote structural studies on disulfide transfer process is a reversible chemical reaction the pharmacologically highly relevant class
    [Show full text]
  • Closer to Europe — Tremendous Opportunities Close By: Germany Is Applying Interview – a Conversation with Bfarm Executive Director Prof
    CLOSER TO EUROPE The new home of the European Medicines U E Agency (EMA) should be located centrally . E within Europe. Optimally accessible. P Set within a strong neigh bourhood. O R Germany is applying for the city of Bonn, U E at the heart of the European - O T Rhine Region, to be the location - R E of the EMA’s new home. S LO .C › WWW FOREWORD e — Federal Min öh iste Gr r o nn f H a e rm al e th CLOSER H TO EUROPE The German application is for a very European location: he EU 27 will encounter policy challenges Healthcare Products Regulatory Agency. The Institute Bonn. A city in the heart of Europe. Extremely close due to Brexit, in healthcare as in other ar- for Quality and Efficiency in Health Care located in T eas. A new site for the European Medicines nearby Cologne is Europe’s leading institution for ev- to Belgium, the Netherlands, France and Luxembourg. Agency (EMA) must be found. Within the idence-based drug evaluation. The Paul Ehrlich Insti- Situated within the tri-state nexus of North Rhine- EU, the organisation has become the primary centre for tute, which has 800 staff members and is located a mere drug safety – and therefore patient safety. hour and a half away from Bonn, contributes specific, Westphalia, Hesse and Rhineland-Palatinate. This is internationally acclaimed expertise on approvals and where the idea of a European Rhine Region has come to The EMA depends on close cooperation with nation- batch testing of biomedical pharmaceuticals and in re- life.
    [Show full text]
  • Membrane Protein Production for Structural Analysis
    Chapter 1 Membrane Protein Production for Structural Analysis Isabelle Mus-Veteau, Pascal Demange and Francesca Zito 1.1 Introduction Integral membrane proteins (IMPs) account for roughly 30 % of all open reading frames in fully sequenced genomes (Liu and Rost 2001). These proteins are of main importance to living cells. They are involved in fundamental biological processes like ion, water, or solute transport, sensing changes in the cellular environment, signal transduction, and control of cell–cell contacts required to maintain cellular homeostasis and to ensure coordinated cellular activity in all organisms. IMP dys- functions are responsible for numerous pathologies like cancer, cystic fibrosis, epi- lepsy, hyperinsulinism, heart failure, hypertension, and Alzheimer diseases. How- ever, studies on these and other disorders are hampered by a lack of information about the involved IMPs. Thus, knowing the structure of IMPs and understanding their molecular mechanism not only is of fundamental biological interest but also holds great potential for enhancing human health. This is of paramount importance in the pharmaceutical industry, which produces many drugs that bind to IMPs, and recognizes the potential of many recently identified G-protein-coupled receptors (GPCRs), ion channels, and transporters, as targets for future drugs. GPCR, which account for 50 % of all drug targets, is one of the largest and most diverse IMP families encoded by more than 800 genes in the human genome (Fredriksson et al. 2003; Lundstrom 2006). However, whereas high-resolution structures are avail- able for a myriad of soluble proteins (more than 42,000 in the Protein Data Bank, I. Mus-Veteau () Institute for Molecular and Cellular Pharmacology, UMR-CNRS 7275, University of Nice-Sophia Antipolis, Valbonne, France e-mail: [email protected] P.
    [Show full text]
  • The Prevention, Detection and Treatment of Cancer Are Preeminent Goals in Health Policy
    No. 14 April 2, 2014 (Koh) 50 years of research for life without cancer "The prevention, detection and treatment of cancer are preeminent goals in health policy. The DKFZ is the flagship of cancer research in Germany. It has brought forward the development of new approaches in the prevention, diagnosis and treatment of cancer. The DKFZ is an institution that, ever since its inception, has promoted creativity and helped innovative ideas flourish. I congratulate the DKFZ with all its employees on these accomplishments." These were the opening words of the Federal Minister of Education and Research, Prof. Dr. Johanna Wanka, in her welcome address at a press conference held in Berlin on the occasion of the 50th anniversary of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ). "The German Cancer Research Center (DKFZ), founded in 1964 in Heidelberg as a national research institute, has seen astonishing changes over those 50 years and has evolved into an internationally renowned center of high-end research," said Otmar Wiestler, Chairman of the Management Board and Scientific Director of DKFZ. From the very beginning, the Center, which was initially not linked to clinics, has had a double mission: to conduct research on the basic biological mechanisms of cancer and translate the results of its research into enhanced methods for the prevention, diagnosis and treatment of cancer. While the initial years were clearly focused on basic research, the DKFZ has gone on to achieve amazing accomplishments in the translation of its research findings into clinical applications. A crucial factor that has facilitated this development was the foundation of the National Center for Tumor Diseases (NCT) Heidelberg in collaboration with Heidelberg University Hospitals and German Cancer Aid (Deutsche Krebshilfe).
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]
  • Nanodiscs in Membrane Biochemistry and Biophysics
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Chem Rev Manuscript Author . Author manuscript; Manuscript Author available in PMC 2018 March 22. Published in final edited form as: Chem Rev. 2017 March 22; 117(6): 4669–4713. doi:10.1021/acs.chemrev.6b00690. NANODISCS IN MEMBRANE BIOCHEMISTRY AND BIOPHYSICS Ilia G. Denisov and Stephen G. Sligar Department of Biochemistry and Department of Chemistry, University of Illinois, Urbana, IL, 61801 Abstract Membrane proteins play a most important part in metabolism, signaling, cell motility, transport, development, and many other biochemical and biophysical processes which constitute fundamentals of life on molecular level. Detailed understanding of these processes is necessary for the progress of life sciences and biomedical applications. Nanodiscs provide a new and powerful tool for a broad spectrum of biochemical and biophysical studies of membrane proteins and are commonly acknowledged as an optimal membrane mimetic system which provides control over size, composition and specific functional modifications on nanometer scale. In this review we attempted to combine a comprehensive list of various applications of Nanodisc technology with systematic analysis of the most attractive features of this system and advantages provided by Nanodiscs for structural and mechanistic studies of membrane proteins. Table of Content Figure An Introduction to Nanodiscs Membrane proteins are represented by a tremendous variety of sizes, structures and functions, including complex supra-molecular
    [Show full text]
  • Antagonist Functional Selectivity: 5-Ht2a
    JPET Fast Forward. Published on July 7, 2011 as DOI: 10.1124/jpet.111.183780 JPETThis Fast article Forward. has not been Published copyedited and on formatted. July 7, The 2011 final as version DOI:10.1124/jpet.111.183780 may differ from this version. JPET#183780 ANTAGONIST FUNCTIONAL SELECTIVITY: 5-HT2A SEROTONIN RECEPTOR ANTAGONISTS DIFFERENTIALLY REGULATE 5-HT2A RECEPTOR PROTEIN LEVEL IN VIVO Prem N. Yadav, Wesley K. Kroeze, Martilias S. Farrell and Bryan L. Roth Downloaded from Departments of Pharmacology (.PN.Y.,W.K.K., M.S.F., B.L.R.,), Medicinal Chemistry jpet.aspetjournals.org (B.L.R.) and Psychiatry (B.L.R.), and Program in Neurosciences and NIMH Psychoactive Drug Screening Program(B.L.R.), University of North Carolina - Chapel Hill Medical School, Chapel Hill, NC 27759 at ASPET Journals on September 29, 2021 1 Copyright 2011 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on July 7, 2011 as DOI: 10.1124/jpet.111.183780 This article has not been copyedited and formatted. The final version may differ from this version. JPET#183780 Running title: Functional Selectivity of 5-HT2A receptor antagonists Corresponding Author: Bryan L. Roth MD, PhD Department of Pharmacology UNC Chapel Hill Medical School 4072 Genetic Medicine Building 120 Mason Farm Road Chapel Hill, NC 27599 Fax: 919-843-5788 Downloaded from Tel: 919-966-7535 (Office) Email: [email protected] ; Number of text pages: 26 jpet.aspetjournals.org Number of tables: 0 Number of figures: 5 Number of references: 39 at ASPET Journals on September 29, 2021 Nnumber of words: Abstract: 157 Introduction: 666, Discussion : 485 Abbreviations: 5-HT2A (serotonin 2A); PCP (phencyclidine)", GPCR (G Protein Coupled Receptor) Recommended section: Neuropharmacology 2 JPET Fast Forward.
    [Show full text]
  • 2-Adrenergic Receptor Is Determined by Conformational Equilibrium in the Transmembrane Region
    ARTICLE Received 21 Mar 2012 | Accepted 2 Aug 2012 | Published 4 Sep 2012 DOI: 10.1038/ncomms2046 Efficacy of theβ 2-adrenergic receptor is determined by conformational equilibrium in the transmembrane region Yutaka Kofuku1,2, Takumi Ueda1, Junya Okude1, Yutaro Shiraishi1, Keita Kondo1, Masahiro Maeda3, Hideki Tsujishita3 & Ichio Shimada1,4 Many drugs that target G-protein-coupled receptors (GPCRs) induce or inhibit their signal transduction with different strengths, which affect their therapeutic properties. However, the mechanism underlying the differences in the signalling levels is still not clear, although several structures of GPCRs complexed with ligands determined by X-ray crystallography are available. Here we utilized NMR to monitor the signals from the methionine residue at position 82 in neutral antagonist- and partial agonist-bound states of β2-adrenergic receptor (β2AR), which are correlated with the conformational changes of the transmembrane regions upon activation. We show that this residue exists in a conformational equilibrium between the inverse agonist- bound states and the full agonist-bound state, and the population of the latter reflects the signal transduction level in each ligand-bound state. These findings provide insights into the multi-level signalling of β2AR and other GPCRs, including the basal activity, and the mechanism of signal transduction mediated by GPCRs. 1 Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan. 2 Japan Biological Informatics Consortium (JBIC), Tokyo 135-0064, Japan. 3 Shionogi Co., Ltd., Discovery Research Laboratories, Osaka 561-0825, Japan. 4 Biomedicinal Information Research Center (BIRC), National Institute of Advanced Industrial Science and Technology (AIST), Aomi 2-41-6, Koto-ku, Tokyo 135-0064, Japan.
    [Show full text]
  • Pharmacology and Therapeutics of Bronchodilators
    1521-0081/12/6403-450–504$25.00 PHARMACOLOGICAL REVIEWS Vol. 64, No. 3 Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics 4580/3762238 Pharmacol Rev 64:450–504, 2012 ASSOCIATE EDITOR: DAVID R. SIBLEY Pharmacology and Therapeutics of Bronchodilators Mario Cazzola, Clive P. Page, Luigino Calzetta, and M. Gabriella Matera Department of Internal Medicine, Unit of Respiratory Clinical Pharmacology, University of Rome ‘Tor Vergata,’ Rome, Italy (M.C., L.C.); Department of Pulmonary Rehabilitation, San Raffaele Pisana Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy (M.C., L.C.); Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UK (C.P.P., L.C.); and Department of Experimental Medicine, Unit of Pharmacology, Second University of Naples, Naples, Italy (M.G.M.) Abstract............................................................................... 451 I. Introduction: the physiological rationale for using bronchodilators .......................... 452 II. ␤-Adrenergic receptor agonists .......................................................... 455 A. A history of the development of ␤-adrenergic receptor agonists: from nonselective ␤ Downloaded from adrenergic receptor agonists to 2-adrenergic receptor-selective drugs.................... 455 ␤ B. Short-acting 2-adrenergic receptor agonists........................................... 457 1. Albuterol........................................................................ 457
    [Show full text]
  • Immunosensation the Immune Sensory System Bonn Cluster of Excellence
    ImmunoSensation the immune sensory system Bonn cluster of excellence ANNUAL REPORT 2013 G Ap(3’-5’)G Gp(2’-5’)A A cGAMP DNA cGAS pppGp(2'-5')A GTP ATP universitätbonn ANNUAL REPORT 2013 Preface p. 8 OVERVIEW Overview: Science and Structure p. 12 Scientific Reports – Research Highlights DNA Sensing and Oxidative Damage p. 16 Local Immune Regulation in Tissues p. 24 Sterile Inflammation in the Nervous System and Metabolism p. 36 Immune Sensing and Responses in Tumor Biology p. 50 Feature Article: Immunity and Aerospace Medicine p. 56 Interviews p. 60 Dean of the Medical Faculty: Prof. Max Baur, MD p. 61 Speaker: Prof. Gunther Hartmann, MD p. 64 Vice-Speaker: Prof. Waldemar Kolanus, PhD p. 66 Postdoc: Katharina Hochheiser, PhD p. 68 PhD Student: Larisa Labzin p. 72 Head of the Flow Cytometry Core Facility: Dr. Elmar Endl p. 76 Cluster Coordination Reports p. 80 Family Support & Gender Equality p. 81 Young Investigator Support p. 86 Public Relations p. 90 Events p. 92 First Retreat of the ImmunoSensation Cluster in St. Goar p. 93 Cluster Seminars p. 95 ImmunoSensation visits ELSC/Israel p. 98 Cluster Science Day p. 102 Prizewinners of the Cluster Science Day p. 104 List of Publications p. 110 Seminars & Meetings p. 124 Prizes & Distinctions p. 128 List of Cluster Members p. 132 Biosketches p. 140 Impressions Retreat St. Goar p. 168 Organigram – Structure of the Cluster p. 170 Participating Institutions p. 172 Cluster Coordination Office (CCO) p. 174 Imprint p. 176 Preface Preface We can now look back on the first year just at the edge of a profound conceptual of funding of our Cluster of Excellence advance arising from new interactions ImmunoSensation by the German within the Cluster, such as the one Research Foundation, DFG.
    [Show full text]